On 11 December 2023, Lisheng Pharmaceutical and Lisheng Investment entered into the Partnership Agreement with Bozheng Capital, Tianjin Jinjia and Tianjin Handeway in relation to the proposed formation of the Limited Partnership Fund, to principally invest in the sector of healthcare, focusing on small molecule and innovative drugs, biopharmaceuticals, high-end preparations, high-end medical equipment as well as medical services. The principal terms of the Partnership Agreement are summarised as follows: Parties: Bozheng Capital (as general partner); Lisheng Investment (as general partner) (collectively, the General Partners, each a General Partner); Lisheng Pharmaceutical (as limited partner); Tianjin Jinjia (as limited partner); Tianjin Handeway (as limited partner); (collectively, the Limited Partners, each a Limited Partner) Name of the Limited Partnership Fund: Tianjin Bozheng Lisheng Health Equity Investment Fund (Limited Partnership). Operation scope: Venture capital and equity investment; Investment scope: The Limited Partnership Fund shall principally invest in the sector of healthcare, focusing on small molecule and innovative drugs, biopharmaceuticals, high-end preparations, high-end medical equipment as well as medical services.

Term: The term of the Limited Partnership Fund shall be five years, in which the first three years are investment period and the final two years are exit period. The term of the Limited Partnership Fund can be extended by two years by unanimous consent of all General Partners, and can be further extended by unanimous consent of all General Partners and the passing of a resolution at a Partners' meeting. Profit distribution: Distributable income shall be distributed in the following order: distribution shall first be made to each of the Partners in proportion to its respective paid-up capital contribution at the time of the distribution until all Partners have recovered their respective paid-up capital contribution; distribution shall then be made to each of the Partners until the cumulative amount received by each of the Partners reaches an amount equivalent to a simple interest of 8% per annum on its respective paid-up capital contribution; out of the remaining distributable income (the Remaining Distributable Income)(if any), 80% shall be distributed among all the Partners in proportion to their respective paid-up capital contribution, 14% shall be distributed to Bozheng Capital in its capacity of the manager as performance-based remuneration, and 6% shall be distributed to Lisheng Investment as excess income.

Loss sharing: Any loss incurred by the Limited Partnership shall be borne by each Partners in proportion to their respective committed capital contribution.